FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 275 filers reported holding FATE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.99 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $238,332 | +136.3% | 63,725 | +34.0% | 0.01% | +100.0% |
| Q3 2023 | $100,840 | -17.3% | 47,566 | +85.7% | 0.00% | 0.0% |
| Q2 2023 | $121,908 | -90.4% | 25,611 | -88.5% | 0.00% | -91.4% |
| Q1 2023 | $1,268,826 | +204.5% | 222,601 | +439.0% | 0.04% | +191.7% |
| Q4 2022 | $416,687 | -40.2% | 41,297 | +32.7% | 0.01% | -47.8% |
| Q3 2022 | $697,000 | -23.7% | 31,111 | -15.6% | 0.02% | -14.8% |
| Q2 2022 | $913,000 | -31.2% | 36,850 | +7.5% | 0.03% | 0.0% |
| Q1 2022 | $1,328,000 | -23.9% | 34,264 | +15.0% | 0.03% | -20.6% |
| Q4 2021 | $1,744,000 | +19.6% | 29,799 | +21.1% | 0.03% | -8.1% |
| Q3 2021 | $1,458,000 | +767.9% | 24,598 | +1106.4% | 0.04% | +516.7% |
| Q1 2021 | $168,000 | -83.4% | 2,039 | -81.7% | 0.01% | -87.2% |
| Q4 2020 | $1,013,000 | +41.1% | 11,142 | -38.0% | 0.05% | +14.6% |
| Q3 2020 | $718,000 | – | 17,960 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |